Literature DB >> 1793018

Pharmacological properties of five diclofenac metabolites identified in human plasma.

I Wiesenberg-Boettcher1, J Pfeilschifter, A Schweizer, A Sallmann, P Wenk.   

Abstract

Five metabolites of diclofenac sodium (Voltarol) have been identified in human plasma. All five metabolites were more than 50 times less potent than diclofenac in inhibiting PGE2 production in zymosan-stimulated mouse macrophages and LTC4 synthesis was not inhibited in these cells. Anti-inflammatory activity (adjuvant arthritis and carragheenan-induced paw oedema in rats) and analgesic activity (phenyl-p-benzoquinone writhing, mouse) of the metabolites were at least 10 times lower when compared to diclofenac. There was a good correlation between in vitro PGE2 inhibition and in vivo activities for diclofenac and its metabolites indicating that inhibition of prostaglandin synthesis is a major mechanism responsible for their pharmacological actions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1793018     DOI: 10.1007/bf01993259

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

1.  Combined automated writhing/motility test for testing analgesics.

Authors:  A Schweizer; R Brom; H Scherrer
Journal:  Agents Actions       Date:  1988-02

2.  Pharmacological properties of diclofenac sodium and its metabolites.

Authors:  R Menassé; P R Hedwall; J Kraetz; C Pericin; L Riesterer; A Sallmann; R Ziel; R Jaques
Journal:  Scand J Rheumatol Suppl       Date:  1978

3.  Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites.

Authors:  H Stierlin; J W Faigle; A Sallmann; W Küng; W J Richter; H P Kriemler; K O Alt; T Winkler
Journal:  Xenobiotica       Date:  1979-10       Impact factor: 1.908

4.  Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile.

Authors:  H Stierlin; J W Faigle
Journal:  Xenobiotica       Date:  1979-10       Impact factor: 1.908

5.  A new metabolite of diclofenac sodium in human plasma.

Authors:  J W Faigle; I Böttcher; J Godbillon; H P Kriemler; E Schlumpf; W Schneider; A Schweizer; H Stierlin; T Winkler
Journal:  Xenobiotica       Date:  1988-10       Impact factor: 1.908

6.  The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound.

Authors:  I Wiesenberg-Boettcher; A Schweizer; J R Green; K Mueller; F Maerki; J Pfeilschifter
Journal:  Drugs Exp Clin Res       Date:  1989

7.  Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients.

Authors:  P H Degen; W Dieterle; W Schneider; W Theobald; U Sinterhauf
Journal:  Xenobiotica       Date:  1988-12       Impact factor: 1.908

Review 8.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

  8 in total
  1 in total

1.  [Acute coronary syndrome after diclofenac induced coronary spasm].

Authors:  A Wieckhorst; A Tiroke; M Lins; A Reinecke; G Herrmann; D Krüger; R Simon
Journal:  Z Kardiol       Date:  2005-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.